Swissmedic Reaffirms Titanium Dioxide Use in Medicinal Products

On November 5, 2025, Swissmedic announced that titanium dioxide will remain authorized as an excipient for…

Swissmedic Opens Bids for Advanced Document and Records Management System: A Regulatory Update

On November 3, 2025, Swissmedic, the Swiss agency for therapeutic products, announced its initiative to procure…

Swissmedic Publishes November Safety Updates for Healthcare Professionals

Swissmedic has issued new safety-related updates this November 2025, designed to inform healthcare professionals and regulatory…

Swissmedic Updates Key Information on Drug Safety Reporting – What You Need to Know

Swissmedic has announced an update to its Drug Safety Reporting Duties in Switzerland information sheet. The…

Swissmedic Updates Signal Management Guidance in PSUR Reporting

Swissmedic has released an update to its guidance document regarding the Authorisation PSUR Signal Management TAM…

Swissmedic Grants Initial Authorisation for Filsuvez®: A Key Milestone in Advanced Therapies

Swissmedic, the Swiss agency for therapeutic products, has announced the first authorisation of Filsuvez®, marking a…

Swissmedic Announces New Role for Laboratory IT Systems Specialist in OMCL

Swissmedic, Switzerland’s surveillance authority for medicines and medical devices, has disclosed an exciting new opportunity in…

Swissmedic Authorises New Therapeutic Use for Trecondi®

Swissmedic has announced an update regarding the medication Trecondi®. On October 31, 2025, the regulatory body…

Swissmedic Grants First Authorisation for SWAN-PSMA-1007®: Key Regulatory Insights

On October 31, 2025, Swissmedic announced the first authorisation of SWAN-PSMA-1007®, marking a significant regulatory milestone.…

Swissmedic Updates Position Paper on Decentralised Clinical Trials: Key Changes Explained

On October 31, 2025, Swissmedic and swissethics announced an update to their position paper on decentralised…